Dawson James downgraded Mednax MD from Buy to Neutral and removed the price target of $80.00.
Dawson James noted, "Mednax' shares currently trade on par or at a premium to our industry group in terms of price/earnings valuation multiples (based on 2012A and 2013E) and multiple of price/revenues for 2013E, although at a discount related to multiple of book value, perhaps due to the large amount of goodwill and other intangibles on Mednax' most recent balance sheet. Thus, we are lowering our rating on MD shares to Neutral from Buy due to the valuation metrics... due to the declining operating margins."
Mednax closed at $86.70 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in